The authors evaluated the impact of macular fluid features on visual and anatomical outcomes in type 3 macular neovascularization (MNV) patients treated with anti-VEGF. They found that the macular fluid morphology, specifically subretinal fluid, in type 3 MNV showed no significant correlation with visual and anatomical outcomes during anti-VEGF treatment.
[Scientific Reports]